John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on Nuvalent. The associated price target remains the same with $126.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
John Newman’s rating is based on Nuvalent’s advancing pipeline and clear visibility toward multiple late-stage catalysts. He sees strong potential in neladalkib, with upcoming ALKOVE-1 progression-free survival results at ASCO expected to demonstrate an advantage over existing options and to underpin revenue from a planned 2027 launch in TKI pre-treated patients.
He also highlights zidesamtinib as a key value driver, with a potential U.S. approval and 2L+ launch by late 2026, followed by a line-agnostic filing supported by compelling intracranial efficacy data. In addition, NVL-330 and a fourth yet-to-be-disclosed program could position Nuvalent as a leading precision oncology player, supporting his unchanged $126 price target and Buy recommendation.
In another report released today, Guggenheim also reiterated a Buy rating on the stock with a $151.00 price target.